Conduct↦Monitoring↦Routine Monitoring Visit↦Follow-Up
Was betrifft es? Warum ist das wichtig?
After a Routine-Monitoring-Visit (RMV), the monitor follows-up on site progress in order to ensure outstanding RMV findings are properly addressed. The aim is to ensure the ongoing right and safety (i.e. study risk-benefit) of study participant, including and the confidentiality and quality of study data.
During RMV follow-up, the site is expected to resolve outstanding issues within a given timeline. This is especially the case regarding serious findings (e.g. safety and quality concerns).
In the event a RMV finding cannot be resolved during follow-up, the SP-INV performs a risk-assessment in order to decide whether the study must:
- Be put on hold until an acceptable resolution of the finding is found
- Be adapted in order control for the finding. An adaptation in study conduct will require a protocol amendment with subsequent approval by Ethics Committee (EC) and if applicable RA (e.g. Swissmedic). In the event participants become affected, they may also have to reconsent
Was muss ich befolgen?
As a study monitor responsible for site follow-up:
- Write a short follow-up letter or e-mail to the Site-INV and:
- Transmit the follow-up letter/e-mail within 10 to 20 business days, or as soon as possible in the event of serious findings
- Remotely check and answer ingoing queries regarding outstanding issues
- Inform the study SP-INV of findings that remain unresolved, or in the event of site non-compliance
Follow-up activities may address the:
- Disposal or accountability of the investigational therapeutic product (e.g. IMP / IMD) or material (e.g. vaccination vials, unused /returned tablets, dysfunctional medical device)
- Ordering of investigational product or other study material including delivery at study site
- The forwarding of essential documents needed for ISF filing
- Update the study TMF (e.g. monitoring report, new staff qualification and training)
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- Glossary: definition monitoring
- Glossary: definition monitoring report
- 3.10.1.3 Risk control
- 3.11.4 Monitoring
- 3.11.4.5 Monitoring activities
- 3.11.4.5.1 Communication with parties conducting the trial
ICH E8 – see in particular guideline
- 6.3 Study reporting
- 6.2.1 Safety monitoring
ISO 14155 Medical Device – see in particular section (access liable to costs)
- 9.2.4 Monitoring